Home » Postmarketing Draft Guidance Needs Details, Industry Says
Postmarketing Draft Guidance Needs Details, Industry Says
November 24, 2009
Stakeholders are telling the FDA that a July draft guidance on postmarketing studies should have described the safety signals the agency uses to determine
that a postmarket clinical trial or study will be required.